Reset filter
Keywords
Multiple Myeloma ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

354 Search results.

Relevance Rating New first Old first

Eligibility Multiple Myeloma NCT01432353

- 9/22/21 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria,Exclusion Criteria
A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT01432353

Eligibility Thrombocytopenia NCT01484314

- 9/22/21 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria,Exclusion Criteria
Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT01484314

Safety and Activity of SRT501 Alone or in Combination with Bortezomib in Patients with Multiple Myeloma NCT00920556 - Screening - Demography; Inclusion Criteria; Exclusion Criteria

- 9/20/21 - 1 form, 4 itemgroups, 34 items, 1 language
Itemgroups: Administrative,Demography,Inclusion Criteria,Exclusion Criteria
Study ID: 113222 Clinical Study ID: 113222 Study Title: A Phase II, Open Label, Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination with Bortezomib in Patients with Multiple Myeloma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00920556 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name:5.0g SRT501 Trade Name: Bortezomib Study Indication: Multiple Myeloma

Eligibility DRKS00003823 NCT00478777 Relapsed or Refractory Multiple Myeloma - Eligibility

- 9/20/21 - 1 form, 2 itemgroups, 27 items, 2 languages
Itemgroups: Inclusion Criteria,Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00478777

Eligibility Multiple Myeloma NCT00590603

- 9/20/21 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria,Exclusion Criteria
Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00590603

Eligibility Multiple Myeloma NCT00642395

- 9/20/21 - 1 form, 2 itemgroups, 21 items, 1 language
Itemgroups: Inclusion Criteria,Exclusion Criteria
Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT); ODM derived from: https://clinicaltrials.gov/show/NCT00642395

Multiple Myeloma Lenalidomide Melphalan NCT01090089 - Eligibility

- 9/20/21 - 1 form, 2 itemgroups, 50 items, 2 languages
Itemgroups: Inclusion Criteria,Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01090089 The Combination of Lenalidomide and Dexamethasone With or Without Intensification by High-dose Melphalan in the Treatment of Multiple Myeloma

Eligibility Multiple Myeloma NCT00086216

- 9/20/21 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria,Exclusion Criteria
Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00086216

Screening Visit LenaMain-Study - Screening visit

- 9/20/21 - 1 form, 3 itemgroups, 51 items, 1 language
Itemgroups: Medical history,Initial diagnosis: Multiple myeloma,Vital signs
A randomised comparison of daily 25 mg versus 5 mg lenalidomide as maintenance therapy after high-dose therapy and autologous stem cell transplantation in patients with multiple myeloma. Protocol-Code: RV-MM-PI-280 EudraCT-Number: 2007-003945-33 Author: Claus Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr. med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann, Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-Studie: Prof. Roland Fenk, Düsseldorf Coordinating center for clinical trial Medical faculty of University Hospital Heinrich-Heine-University Scientific Director: Herr Dr. J. Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0) 211-81-19701 Fax: +49 (0) 211-81-19702

Multiple Myeloma Adverse Event NCT00522392 - Adverse Event Multiple Myeloma (CTCAE v3) E1A05 Form 2861 NCT00522392

- 9/20/21 - 1 form, 6 itemgroups, 24 items, 1 language
Itemgroups: Header,ON TREATMENT,Adverse Event,Adverse event blood, bone marrow lab,Adverse event infection,Other Adverse Events
E1A05 Adverse Event Form (CTCAE v3) - Form 2861 Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone NCT00522392 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=32B7FEFD-31B1-3074-E044-0003BA3F9857

Multiple Myeloma NCT00602641 - Adverse Event Multiple Myeloma (CTCAE v3) E1A06 NCT00602641

- 9/20/21 - 1 form, 5 itemgroups, 23 items, 1 language
Itemgroups: Header,ON TREATMENT,Adverse Event,Adverse event blood, bone marrow lab,Adverse event infection
E1A06 Adverse Event Form (CTCAE v3) Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma NCT00602641 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=406515E8-0840-569A-E044-0003BA3F9857

Eligibility NCT00689936 Multiple Myeloma - Eligibility

- 9/20/21 - 1 form, 2 itemgroups, 47 items, 2 languages
Itemgroups: Inclusion Criteria,Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00689936

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial